The FDA has approved esketamine nasal spray as an adjunctive therapy for adults with treatment-resistant depression (TRD), which affects approximately 30% of patients with major depressive disorder. It’s the first regulatory approval of esketamine, the s-enantiomer of ketamine, for any psychiatric condition worldwide.
Sancar F. New Therapy for Treatment-Resistant Depression. JAMA. 2019;321(15):1449. doi:10.1001/jama.2019.3596
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: